---
reference_id: "PMID:40855389"
title: "Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies."
authors:
- Moshkovich M
- Andrade LF
- Anderson M
- Yosipovitch G
journal: Am J Clin Dermatol
year: '2025'
doi: 10.1007/s40257-025-00979-z
content_type: abstract_only
---

# Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies.
**Authors:** Moshkovich M, Andrade LF, Anderson M, Yosipovitch G
**Journal:** Am J Clin Dermatol (2025)
**DOI:** [10.1007/s40257-025-00979-z](https://doi.org/10.1007/s40257-025-00979-z)

## Content

1. Am J Clin Dermatol. 2025 Nov;26(6):895-903. doi: 10.1007/s40257-025-00979-z. 
Epub 2025 Aug 25.

Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic 
Strategies.

Moshkovich M(1), Andrade LF(2), Anderson M(3), Yosipovitch G(4).

Author information:
(1)Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
(2)Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami 
Itch Center, University of Miami Miller School of Medicine, 1600 NW 10th Ave 
RMSB 2023A, Miami, FL, 33136, USA.
(3)Birmingham Heersink School of Medicine, University of Alabama, Tuscaloosa, 
AL, USA.
(4)Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami 
Itch Center, University of Miami Miller School of Medicine, 1600 NW 10th Ave 
RMSB 2023A, Miami, FL, 33136, USA. yosipog@gmail.com.

Lichen simplex chronicus (LSC), also known as neurodermatitis, is a common 
chronic pruritic dermatosis defined by lichenified plaques resulting from 
persistent scratching. Though often secondary to underlying dermatologic, 
systemic, or psychological triggers, LSC represents a distinct clinical entity 
with significant morbidity. The hallmark itch-scratch cycle contributes not only 
to visible skin changes but also to substantial sleep disruption, emotional 
distress, and functional impairment. Psychological stress, anxiety, and 
depression are frequent comorbidities and can further perpetuate disease 
chronicity. This review provides a comprehensive summary of the evolving 
understanding of LSC, from its neuroimmune-driven pathogenesis to the wide 
spectrum of therapeutic strategies currently available. In addition to topical 
corticosteroids, novel approaches including immunomodulators, neuromodulators, 
Janus kinase (JAK) inhibitors, and biologics are being increasingly explored. 
Procedural therapies such as cryotherapy, fractional laser resurfacing, and 
botulinum toxin injections, have also emerged as valuable tools, particularly in 
treatment-refractory cases. Recent insights into type 2 inflammation and 
dysregulated sensory pathways have informed the rationale for these targeted 
strategies. In anatomically sensitive areas such as the genital region, where 
topical agents may be poorly tolerated, systemic treatments may be required. 
Given this complexity, individualized, multimodal treatment plans are critical 
to optimizing management and improving quality of life (QoL) in patients with 
LSC. By synthesizing current data on pathophysiology, diagnosis, and both 
established and emerging therapies, this review aims to guide clinicians in 
optimizing care for patients with LSC and addressing its far-reaching 
psychosocial burden.

Â© 2025. The Author(s).

DOI: 10.1007/s40257-025-00979-z
PMCID: PMC12615567
PMID: 40855389 [Indexed for MEDLINE]

Conflict of interest statement: Declarations. Conflict of interest: G.Y. is a 
consultant and advisory Board member for Sanofi, Regeneron, Pfizer, Galderma, 
Novartis, Eli Lilly, AbbVie, Arcutis, Abbvie, Kiniksa, Trevi, Pierre Fabre, LEO 
Pharma, Escient, Celldex,Kamari and Vifor ; and has received research support 
from Abbvie, Pfizer, Sanofi, Regeneron, LEO Pharma, Eli Lilly, Kiniksa, 
Novartis, Escient, , Galderma and Celldex. G.Y. is an Editorial Board member of 
the American Journal of Clinical Dermatology. He was not involved in the 
selection of peer reviewers for the manuscript nor any of the subsequent 
editorial decisions. Availability of data and material: No new datasets were 
generated or analyzed during the current study. All data discussed are derived 
from previously published literature and are available within the referenced 
sources. Ethics approval: Not applicable Consent to participate: Not applicable. 
Consent for publication: The authors obtained consent from patients for their 
anonymized photos to be published in print and online and with the understanding 
that this information may be publicly available. Code availability: Not 
applicable. Author contributions: M.M. was responsible for the primary 
literature review and drafting of the manuscript. L.F.A. and M.A. contributed to 
the literature review and assisted with manuscript editing. G.Y. supervised the 
project, provided critical revisions, and ensured clinical and academic 
accuracy. All authors have read and approved the final version of the manuscript 
and agree to be accountable for all aspects of the work.